Current AASLD guidelines recommend surveillance in adults with cirrhosis and high-risk patients without cirrhosis using ultrasound with or without alpha-fetoprotein (AFP) assessment at six-month intervals [4]. The gene discussed is AFP; the disease is Cirrhosis.